Np Test 1: Chest Disorders (Respiratory)

Inhaled corticosteroids are used to treat COPD by reducing airway inflammation. COPD is characterized by chronic inflammation in the airways, which leads to symptoms such as coughing, wheezing, and shortness of breath. Inhaled corticosteroids work by suppressing the immune response in the airways, thereby reducing inflammation and preventing further damage to the respiratory system. This helps to alleviate symptoms and improve lung function in individuals with COPD. Reversal of fixed airway obstruction, improvement of central respiratory drive, and mucolytic activity are not the primary therapeutic actions of inhaled corticosteroids in treating COPD.

Pertussis, also known as whooping cough, is most commonly transmitted through respiratory droplets. When an infected person coughs or sneezes, tiny droplets containing the bacteria are released into the air. These droplets can be inhaled by others who are in close proximity to the infected person, leading to the spread of the infection. Contact with contaminated items, contaminated food, or inhalation of vaporized contaminated water are not the primary modes of transmission for pertussis.

Oral candidiasis is a potential adverse effect from the use of inhaled corticosteroids (ICS). ICS can suppress the immune response in the mouth, leading to an overgrowth of candida, a type of fungus that causes oral thrush. This condition is characterized by the development of white, creamy patches on the tongue, inner cheeks, and other areas of the mouth. It can cause discomfort, difficulty in swallowing, and altered taste sensation. Regular oral hygiene, such as rinsing the mouth after using ICS, can help prevent oral candidiasis.

The findings of increased tactile fremitus and dullness to percussion at the right lung base in a person with CAP likely indicate an area of consolidation. Consolidation refers to the filling of the alveoli with fluid, such as pus or blood, causing the affected lung tissue to become solid. This can occur as a result of pneumonia, where the air sacs in the lungs become inflamed and filled with fluid. The increased tactile fremitus, which is the vibration felt upon palpation, and dullness to percussion, which is the dull sound heard upon tapping the chest, are consistent with the presence of consolidation in the lung.

Azithromycin is the correct answer for the treatment of Community-Acquired Pneumonia (CAP) in a 42-year-old man with no comorbidity and no recent antimicrobial use. Azithromycin is a macrolide antibiotic that is effective against the most common pathogens causing CAP, including Streptococcus pneumoniae and Haemophilus influenzae. It is recommended as a first-line treatment for CAP in otherwise healthy individuals without risk factors for drug-resistant pathogens. Cefpodoxime, trimethoprim-sulfamethoxazole, and ciprofloxacin are alternative treatment options for CAP but are not the preferred choice in this specific case.

The FEV1/FVC ratio equal to or less than 0.70 is the most consistent with the diagnosis of COPD. This ratio represents the percentage of the forced expiratory volume in one second (FEV1) to the forced vital capacity (FVC), and a ratio of 0.70 or less indicates airflow limitation. In COPD, the airways become narrowed and obstructed, leading to difficulty exhaling and reduced FEV1/FVC ratio. Dyspnea on exhalation and an elevated diaphragm on X-ray can also be seen in COPD, but they are not as specific to the diagnosis as the FEV1/FVC ratio. Polycythemia noted on CBC may be seen in COPD due to chronic hypoxemia.

The correct answer is to advise the 64-year-old woman with COPD to receive the inactivated flu vaccine. This is because individuals with COPD are at a higher risk of developing complications from the flu, and the inactivated flu vaccine is safe and effective for them. The inactivated flu vaccine contains killed flu viruses, so there is no risk associated with it. Taking an antiviral for the duration of the flu season may be recommended in some cases, but receiving the inactivated flu vaccine is the primary preventive measure for individuals with COPD.

The correct answer is "A congested cough that is worse during the day." This is because a congested cough is not typically associated with asthma. Asthma is characterized by recurrent spasmodic cough, shortness of breath and chest tightness with exercise, and wheezing with or without respiratory infections. However, a congested cough is more commonly associated with conditions such as the common cold or sinusitis.

Short-acting beta2 agonists work by causing smooth muscle relaxation. When these agonists bind to beta2 receptors in the airway smooth muscle, it leads to the activation of an enzyme called adenylate cyclase, which increases the production of a molecule called cyclic adenosine monophosphate (cAMP). Increased cAMP levels then trigger a cascade of intracellular events that ultimately result in the relaxation of the smooth muscle in the airways. This relaxation helps to open up the airways, making it easier for individuals with conditions such as asthma or chronic obstructive pulmonary disease (COPD) to breathe.

The goal of inhaled corticosteroid use in stage III or severe COPD is to minimize the risk of repeated exacerbations. Inhaled corticosteroids are commonly used in the management of COPD to reduce airway inflammation and prevent exacerbations. By minimizing the risk of exacerbations, these medications can help improve the overall quality of life for individuals with COPD and reduce the need for hospitalizations and emergency room visits. Improving cough function, reversing alveolar hypertrophy, and helping mobilize secretions are not specific goals of inhaled corticosteroid therapy in COPD.

The correct answer is male gender. This means that being a male does not increase the risk for the reactivation of latent TB infection. However, diabetes mellitus, immunocompromise, and long-term oral corticosteroid therapy are all known risk factors for the development of infection reactivation in patients with latent TB infection.

A CXR (chest x-ray) should be obtained when attempting to rule out a concomitant pneumonia in a patient with a COPD exacerbation. This is because pneumonia can be a common complication in patients with COPD, and it is important to identify and treat it promptly. A chest x-ray can help visualize any signs of pneumonia such as infiltrates or consolidation in the lungs. It is not necessary to obtain a CXR routinely in all patients with a COPD exacerbation, but it should be considered when there is suspicion of pneumonia or if the patient's work of breathing is increased.

Propranolol should be avoided in a 36-year-old man with asthma who also needs antihypertensive therapy because it is a non-selective beta-blocker. Non-selective beta-blockers can cause bronchoconstriction and worsen asthma symptoms by blocking beta-2 receptors in the lungs. This can lead to difficulty in breathing and potentially trigger an asthma attack. Therefore, it is not recommended to prescribe propranolol in this case.

Respiratory fluoroquinolones have the quality of activity against drug-resistant S. pneumoniae. This means that these antibiotics are effective in treating infections caused by S. pneumoniae strains that have developed resistance to other types of antibiotics. This is an important quality as drug-resistant strains of S. pneumoniae can cause serious respiratory infections, and having an antibiotic that can effectively treat these infections is crucial for patient care.

During an acute asthma attack, the airways become inflamed and narrowed, making it difficult for air to flow in and out of the lungs. This causes the lungs to work harder to get enough oxygen, leading to hyperinflation. Hyperinflation refers to an increase in lung volume and can be seen on a chest X-ray (CXR) as a flattening of the diaphragm, increased retrosternal airspace, and increased lung markings. It is a characteristic finding in patients with acute asthma attacks. Atelectasis, consolidation, and Kerley B signs are not typically associated with acute asthma attacks.

ABX therapy is usually not indicated for mild acute COPD exacerbation in a 42-year-old man because it is typically caused by viral infections rather than bacterial infections. Antibiotics are only effective against bacterial infections, so they would not be effective in treating a viral exacerbation. Additionally, unnecessary use of antibiotics can contribute to antibiotic resistance and other adverse effects. Therefore, the most appropriate choice for therapy in this case would be to not prescribe antibiotics unless there are specific indications of a bacterial infection.

Long-acting beta 2 agonists should be added to therapy only when ICS use does not provide adequate asthma control. This means that if a patient's asthma symptoms are not well controlled with the use of inhaled corticosteroids (ICS), then long-acting beta 2 agonists can be considered as an additional treatment option. This suggests that long-acting beta 2 agonists are not recommended as a first-line therapy in mild persistent asthma, and they do not have a rapid onset of action compared to short-acting beta 2 agonists. Additionally, long-acting beta 2 agonists may have a different pharmacodynamic profile compared to short-acting beta 2 agonists.

According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) COPD guidelines, a short-acting inhaled bronchodilator is indicated for all stages of COPD. Bronchodilators help to relax and open up the airways, making it easier for individuals with COPD to breathe. Short-acting bronchodilators provide immediate relief and are commonly used as rescue medications for COPD symptoms. They are recommended for all stages of COPD as they can help improve airflow and relieve symptoms such as shortness of breath and wheezing. Other medications like inhaled corticosteroids, mucolytic agents, and theophylline may be indicated for specific stages or as add-on therapies, but a short-acting inhaled bronchodilator is universally recommended.

Theophylline is a medication that is used in the treatment of COPD. It is indicated for use in moderate to very severe cases of COPD. However, its use is limited due to its narrow therapeutic profile and potential for drug-drug interactions. This means that the dosage of theophylline needs to be carefully monitored and adjusted to ensure that it is effective and safe for the individual patient. Additionally, theophylline can interact with other medications, which can further complicate its use. Despite these limitations, theophylline is considered a potent bronchodilator, meaning that it helps to open up the airways and improve breathing in patients with COPD. It is available in various forms, including oral and parenteral formulations.

The correct answer suggests that the potential risk of delayed growth with inhaled corticosteroids (ICS) is outweighed by their effectiveness in treating asthma. This implies that the benefits of using ICS for a child with asthma are greater than the potential side effect of delayed growth.

The cornerstone of moderate persistent asthma drug therapy is the use of inhaled corticosteroids. These medications are considered the most effective long-term control medication for asthma. They work by reducing inflammation in the airways and preventing symptoms such as wheezing, coughing, and shortness of breath. Inhaled corticosteroids are recommended as the first-line treatment for moderate persistent asthma, and they are safe and effective when used as prescribed. Other medications listed, such as oral theophylline, mast cell stabilizers, and short-acting beta2 agonists, may be used as adjunct therapies but are not the primary treatment for moderate persistent asthma.

Levalbuterol (Xopenex) has the ability potentially to provide greater bronchodilation with a lower dose compared to albuterol. This means that it may be more effective in opening up the airways and relieving symptoms of bronchospasm at a lower dosage. This can be beneficial as it may reduce the risk of side effects associated with higher doses of medication.

Doxycycline is the correct answer because it is a tetracycline antibiotic that can be used as an alternative to macrolides in the treatment of community-acquired pneumonia (CAP). It is effective against a wide range of bacteria and is commonly used when macrolides cannot be taken. Amoxicillin is not typically used for CAP treatment, and fosfomycin is not commonly used for respiratory infections. Clarithromycin is a macrolide antibiotic, so it is not suitable for a patient who cannot take macrolides.

After initiating inhaled corticosteroid or leukotriene modifier therapy, it usually takes about 1-2 weeks to see the clinical effects. This means that the medication starts to have an impact on the symptoms or condition being treated within this time frame. It is important to note that individual responses may vary, and some patients may experience the effects sooner or later than the average timeframe mentioned.

Ipratropium bromide (Atrovent) is prescribed in treating COPD to achieve bronchodilation. This medication acts as an anticholinergic, blocking the action of acetylcholine in the airways. By doing so, it relaxes the smooth muscles in the bronchi, leading to the dilation of the airways and improved airflow. This helps to relieve symptoms such as wheezing, shortness of breath, and coughing in patients with COPD.

The therapeutic objective of using inhaled ipratroprium bromide in the treatment of acute asthma exacerbation is the inhibition of muscarinic cholinergic receptors. Ipratropium bromide is an anticholinergic medication that works by blocking the action of acetylcholine, a neurotransmitter that causes constriction of the airways. By inhibiting the muscarinic cholinergic receptors, ipratropium bromide helps to relax and open up the airways, making it easier to breathe. This can provide relief from symptoms such as wheezing, shortness of breath, and chest tightness associated with acute asthma exacerbation.

For patients with stage IV COPD, using home oxygen for at least 15 hours a day is recommended. This is because oxygen therapy can improve symptoms, exercise tolerance, and survival in patients with severe COPD. Using oxygen as needed when experiencing shortness of breath may not provide sufficient oxygenation throughout the day, while using it primarily during sleep hours may not address the oxygen needs during waking hours. Therefore, using home oxygen for at least 15 hours a day is the most appropriate recommendation for this patient.

Respiratory droplet transmission is the best description for the mechanism of transmission in an atypical pneumonia. This means that the infection is spread through respiratory droplets that are expelled when an infected person coughs, sneezes, or talks. These droplets can then be inhaled by others in close proximity, leading to the spread of the infection.

Leukotriene receptor antagonists should be used as inflammatory inhibitors in the treatment of asthma. These medications work by blocking the action of leukotrienes, which are inflammatory substances that contribute to the symptoms of asthma. By inhibiting inflammation, leukotriene receptor antagonists help to reduce airway swelling and mucus production, making it easier for individuals with asthma to breathe. They are not considered to be long-acting bronchodilators, rescue drugs, or interventions in acute inflammation.

Excessive mucus production is a characteristic found in the early stages of chronic bronchitis. Chronic bronchitis is a condition characterized by inflammation and irritation of the bronchial tubes, leading to excessive production of mucus. This excessive mucus can cause coughing, wheezing, and difficulty breathing. Over time, if left untreated, chronic bronchitis can progress to more severe symptoms such as dyspnea at rest, but in the early stages, excessive mucus production is a key characteristic. Enlargement of air spaces distal to the terminal bronchiole is seen in emphysema, alveolar fibrosis is seen in conditions like pulmonary fibrosis, and dyspnea at rest is a later symptom of chronic bronchitis.

In patients with an asthma flare, hyperresonance on thoracic percussion may be expected on physical examination. This is because hyperinflation of the lungs, which occurs during an asthma attack, can lead to increased air trapping in the lungs. This increased air in the lungs causes the sound produced during percussion to be louder and more resonant than normal. Therefore, hyperresonance on thoracic percussion is a characteristic finding in patients with asthma flares.

Azithromycin is the most appropriate choice for abx therapy for a severe COPD exacerbation in a 52-year-old man because it is a macrolide antibiotic that has activity against common respiratory pathogens, including Haemophilus influenzae and Moraxella catarrhalis. It also has anti-inflammatory properties, which can be beneficial in reducing airway inflammation in COPD exacerbations. Additionally, azithromycin has a convenient dosing regimen, with a long half-life, allowing for once-daily dosing for a shorter duration of therapy. Amoxicillin is not the best choice as it primarily covers Streptococcus pneumoniae, which is less commonly associated with COPD exacerbations. Trimethoprim-sulfamethoxazole and fosfomycin are not typically used for COPD exacerbations.

High-dose amoxicillin with a macrolide is the correct answer for the treatment of CAP (community-acquired pneumonia) in a 78-year-old woman with COPD. This combination is recommended as first-line therapy for CAP in older adults with comorbidities such as COPD. Amoxicillin provides coverage against the most common pathogens responsible for CAP, while the addition of a macrolide (such as azithromycin or clarithromycin) helps to cover atypical pathogens like Mycoplasma pneumoniae and Legionella pneumophila. This combination is effective in treating the infection and reducing the risk of complications in this patient population.

The patient's clinical assessment shows improvement, with the absence of fever, improved hydration, and decreased shortness of breath. Additionally, the physical examination reveals peak inspiratory crackles and increased tactile fremitus in the right posterior thorax, indicating resolution of the right lower lobe infiltrate. Therefore, it is appropriate to continue with the current plan of care as the patient is improving.

According to the National Asthma Education and Prevention Program Expert Panel Report-3 (NAEPPEPR-3) guidelines, rural residence is not considered a risk factor for asthma death. The guidelines mention that hospitalization or an emergency department visit for asthma in the past month, current use of systemic corticosteroids or recent withdrawal from systemic corticosteroids, and difficulty perceiving airflow obstruction or its severity are all risk factors for asthma death. However, rural residence is not listed as a risk factor in the guidelines.

Legionella species are primarily transmitted through inhalation of contaminated water. This is because Legionella bacteria thrive in water environments such as hot tubs, cooling towers, and plumbing systems. When these water sources become aerosolized, such as through showers or air conditioning systems, the bacteria can be inhaled into the respiratory system. Once inhaled, Legionella can cause a severe form of pneumonia known as Legionnaires' disease. Other modes of transmission, such as respiratory droplets, contact with contaminated surfaces, or hematogenous spread, are not the primary means of transmission for Legionella species.

The correct answer is that both the influenza and antipneumococcal vaccines should be given today. This is because the patient is hospitalized with community-acquired pneumonia (CAP), which puts them at a higher risk for complications from both influenza and pneumococcal infections. Vaccinating the patient against both diseases will help prevent further illness and potentially serious complications. Delaying the vaccines could put the patient at risk for contracting these infections while they are still vulnerable.

The best plan of care for the 33-year-old woman working in a small office with a man recently diagnosed with active pulmonary TB is for her to receive TB chemoprophylaxis if her TST (tuberculin skin test) result is 5 mm or more in induration. This is because a positive TST result indicates exposure to TB and puts her at risk for developing active TB. Chemoprophylaxis helps to prevent the development of active TB in individuals who have been exposed to the bacteria. Therefore, it is important for her to receive TB chemoprophylaxis if her TST result is positive.

Prednisone 15 mg is the most potent corticosteroid dose among the given options. Potency refers to the strength or effectiveness of a drug. Prednisone is a synthetic corticosteroid that has a higher potency compared to the other options, such as methylprednisolone, triamcinolone, and hydrocortisone. The higher the dose of prednisone, the more potent it is in terms of its anti-inflammatory and immunosuppressive effects. Therefore, in this case, the 15 mg dose of prednisone is the most potent corticosteroid option.

The correct answer is respiratory fluoroquinolone. This is because a 69-year-old man with heart failure and DM II is at a higher risk of complications from community-acquired pneumonia (CAP). Respiratory fluoroquinolones, such as levofloxacin or moxifloxacin, have broad-spectrum activity against the most common pathogens causing CAP, including atypical organisms. They are recommended as first-line treatment in patients with comorbidities, like heart failure and diabetes mellitus type II, due to their efficacy and ability to cover a wide range of potential pathogens.

Patients with emphysema often exhibit enlargement of air spaces distal to the terminal bronchiole. Emphysema is a chronic obstructive pulmonary disease characterized by the destruction of alveolar walls, leading to the formation of larger air spaces. This results in a decrease in the surface area available for gas exchange and impaired lung function. Alpha-1 antiprotease deficiency is a genetic condition that can contribute to the development of emphysema, but it is not the most common characteristic found in patients. Alveolar fibrosis and hypertrophy of the larger airways are not typically associated with emphysema.

The next most appropriate action in this case is to obtain a peak expiratory flow measurement. The patient's symptoms suggest an exacerbation of his asthma, as indicated by the sore throat, clear nasal discharge, body aches, and wheezing. The use of albuterol every 3 hours indicates inadequate control of his symptoms. A peak expiratory flow measurement can help assess the severity of his asthma exacerbation and guide further management decisions, such as the need for systemic corticosteroids or hospitalization. A CXR may be considered if there are additional signs or symptoms suggestive of a respiratory infection or other lung pathology. Oxygen saturation measurement may be obtained concurrently but is not the next most appropriate action. Sputum smear for WBCs is not indicated in this case.

Prednisone is a systemic corticosteroid that helps to reduce inflammation and relieve symptoms in acute asthma flares. It is commonly used in the management of moderate to severe asthma exacerbations. In this case, the patient's symptoms are not well-controlled despite the use of budesonide and albuterol, indicating the need for additional anti-inflammatory therapy. Therefore, adjusting her medications to include prednisone would be appropriate to help improve her symptoms and lung function. Theophylline, salmeterol, and montelukast are also used in the management of asthma but may not provide immediate relief in an acute flare.

Haemophilus influenzae is often implicated in a COPD exacerbation caused by bacterial respiratory tract infection. This pathogen is a common cause of respiratory infections, particularly in patients with chronic obstructive pulmonary disease (COPD). It is known to colonize the respiratory tract and can cause exacerbations by inducing inflammation and damage to the airways. Treatment with appropriate antibiotics targeting Haemophilus influenzae is crucial in managing COPD exacerbations.

The primary mechanism of antimicrobial resistance in H. influenzae is through the organism's beta-lactamase production. Beta-lactamase is an enzyme that inactivates beta-lactam antibiotics, which are commonly used to treat bacterial infections. By producing beta-lactamase, H. influenzae can break down these antibiotics and render them ineffective. This mechanism allows the bacteria to survive and continue to cause infections even in the presence of beta-lactam antibiotics.

The clinical presentation of progressive primary TB commonly includes malaise, fever, and a dry cough. Frank hemoptysis, which refers to the coughing up of blood, is not typically seen in progressive primary TB. This symptom is more commonly associated with advanced stages of TB or other respiratory conditions.

Renal insufficiency is a risk factor for death resulting from pneumonia. Renal insufficiency refers to the inability of the kidneys to properly filter waste and regulate fluid and electrolyte balance. This can weaken the immune system and make individuals more susceptible to infections like pneumonia. Additionally, renal insufficiency can impair the body's ability to eliminate toxins and medications, which may hinder the effectiveness of treatment for pneumonia. Therefore, individuals with renal insufficiency are at a higher risk of complications and death from pneumonia.

The correct answer is Clarithromycin. This is because the patient is a 58-year-old woman with symptoms of community-acquired pneumonia (CAP), including a dry cough, headache, and malaise. Clarithromycin is a suitable choice for treating CAP in this patient because it covers the most common pathogens responsible for CAP, such as Streptococcus pneumoniae and Haemophilus influenzae. Additionally, the patient has no recent antimicrobial use and no comorbidities, which makes clarithromycin an appropriate first-line choice for treatment.

The QuantiFERON-TB Gold test (QTF-G) has potential advantages compared to TST, such as the ability to complete the testing process in one clinical visit, providing results within 24 hours, and eliminating reader bias in test interpretation. However, it does not provide a prediction as to who is at the greatest risk for disease development.

According to the ATS/IDSA guidelines, the usual length of antimicrobial therapy for the treatment of CAP (Community-Acquired Pneumonia) for outpatients is 5-7 days. This means that patients with CAP who are not hospitalized typically require a course of antibiotics for a duration of 5 to 7 days to effectively treat the infection.